Aldeyra Therapeutics/$ALDX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Aldeyra Therapeutics

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Ticker

$ALDX
Sector
Primary listing

Employees

8

ALDX Metrics

BasicAdvanced
$323M
-
-$0.85
0.75
-

What the Analysts think about ALDX

Analyst ratings (Buy, Hold, Sell) for Aldeyra Therapeutics stock.

Bulls say / Bears say

Despite the FDA’s second complete response letter, Aldeyra is continuing two ongoing pivotal reproxalap trials and plans to resubmit its NDA later this year, underscoring a resilient development strategy (Reuters)
Aldeyra’s exclusive option agreement with AbbVie for reproxalap provides a potential $94 million upfront payment and co-development option, offering a crucial non-dilutive funding pathway upon approval (Reuters)
Dry eye disease affects approximately 16.4 million Americans, indicating a sizeable addressable market and multibillion-dollar commercial opportunity for reproxalap if approved (Reuters)
The FDA’s complete response letter marked the second rejection for reproxalap, citing failure to demonstrate efficacy and requiring at least one additional adequate trial, significantly delaying the approval timeline (Reuters)
A late-stage trial involving 132 patients failed to sufficiently prove reproxalap’s efficacy in reducing ocular discomfort, raising questions about the consistency of its clinical data (Reuters)
Following the FDA’s complete response letter, Aldeyra’s shares plunged 73% in premarket trading, reflecting pronounced investor skepticism and high downside risk in the equity (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.

ALDX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ALDX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALDX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs